Actively Recruiting
Study of Linperlisib and Chidamide Compared to Standard CHOP Chemotherapy in Patients With Peripheral T-cell Lymphoma Phase IbII Multicenter Open-Label Trial
Led by Yanyan Liu · Updated on 2025-12-05
134
Participants Needed
6
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of linperlisib and chidamide for treating peripheral T-cell lymphoma PTCL in a multi-phase study. The phase Ib part aims to find the best dose of linperlisib with chidamide. Phase IIa explores how well this combination works and its safety in newly diagnosed patients. Phase IIb compares this combination to the standard CHOP chemotherapy regimen in newly diagnosed PTCL patients. In phase Ib, patients with either new or relapsed PTCL receive fixed chidamide doses twice weekly and escalating linperlisib doses once daily to determine the recommended dose for further study. In phase IIa, newly diagnosed patients receive the recommended dose of linperlisib plus chidamide every three weeks, up to six cycles. Phase IIb randomly assigns newly diagnosed patients to receive either the linperlisib and chidamide combination or the standard CHOP or similar chemotherapy regimen, also for six cycles. Participants undergo an interim assessment after three treatment cycles to check response. Those responding continue for three more cycles. After six cycles, patients may choose stem cell transplantation, maintenance treatment, or observation. Researchers measure response rates, progression-free survival, overall survival, adverse events, and quality of life using questionnaires. The study includes safety follow-up and lasts about three years on average per participant.
CONDITIONS
Brief Title
Linperlisib Combined With Chidamide in Patients With PTCL
Research Team
Y
Yanyan Liu
Z
Zheng Yan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here